Bristol Myers Squibb And Hengrui Pharma Announce Up To $15.2B Global Collaboration With $600M Upfront To Advance 13 Early-Stage Oncology And Immunology Programs

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide

Agreements include 13 programs with the potential to address significant unmet patient needs and support long‑term growth